Business
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%)Q1 2026 total net revenue of $34.7 millionReached settlement with Baxter Healthcare Corporation in CINVANTI® patent litigationReaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million Adjusted EBITDA CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology compan
About this update from Heron Therapeutics, Inc.
[{"type":"image","alt":"Heron Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Heron Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":112,"url":"https://media.zenfs.com/en/globenewswire.com/6d2d3a8a7cac504c195c1610781eea10"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sob9r0MwEzYeSx3TI9R.JA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1Nw--/https://media.zenfs.com/en/globenewswire.com/6d2d3a8a7cac504c195c1610781eea10","width":300,"height":112},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Sob9r0MwEzYeSx3TI9R.JA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1Nw--/https://media.zenfs.com/en/globenewswire.com/6d2d3a8a7cac504c195c1610781eea10","width":300,"height":112}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%)","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Q1 2026 total net revenue of $34.7 million","length":42,"tagName":"p"}]},{"val":[{"type":"text","content":"Reached settlement with Baxter Healthcare Corporation in CINVANTI® patent litigation","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million Adjusted EBITDA","length":100,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":347,"olType":false},{"type":"text","content":"CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates.","length":273,"tagName":"p"},{"type":"text","content":"“Despite typical first-quarter seasonality and unusual weather-related disruption early in the quarter, we saw a clear recovery in February and March,” said Craig Collard, Chief Executive Officer of Heron. “Our Acute Care franchise continues to perform with strong year-over-year growth, and we remain confident in our full-year framework as deferred elective procedures return and our commercial catalysts such as IGNITE 2.0, unique J-Codes, and planned sales force expansion for the Acute Care franchise continue to build through 2026.”","length":538,"tagName":"p"},{"type":"text","co...